APIs Imports from China

1. At a Glance

• Active Pharmaceutical Ingredients (APIs) are the biologically active components in finished drug formulations; India — the "pharmacy of the world" in formulations — remains structurally dependent on China for bulk drugs/APIs and Key Starting Materials (KSMs) [S1][S3].
• Strategic vulnerability: high import concentration from a single geopolitical rival creates health-security, supply-chain and forex risks, prompting the Atmanirbhar Bharat push in pharma since 2020 [S1][S2][S3].

2. Why in the News

• 10 March 2026 PIB release (Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers) tabled the list of APIs where Chinese imports ≥ 70% of India's total API imports in FY 2023-24 and FY 2024-25, reigniting debate on import dependence despite five years of PLI/Bulk Drug Park interventions [S1].

3. Background & Evolution

• March 2020: Cabinet approved twin schemes — PLI for KSMs/DIs/APIs and Scheme for Promotion of Bulk Drug Parks — on 20.03.2020, in the wake of COVID-19 supply disruptions [S2][S3].
• Katoch Committee (2015) earlier flagged India's API import dependence (~70% from China for many critical APIs).
• 2021: First approvals under PLI (Production Linked Incentive) for 41 identified bulk drugs [S2].
• 2022: Three Bulk Drug Parks sanctioned — Gujarat, Himachal Pradesh, Andhra Pradesh [S3].
• 2024-25: 34 of 48 selected PLI projects commissioned, producing 25 bulk drugs [S2].

4. Core Static Facts

• Nodal body: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1].
• PLI Scheme for KSMs/DIs/APIs: Outlay ₹6,940 crore; tenure FY 2020-21 to FY 2029-30; targets 41 critical bulk drugs [S2].
• Bulk Drug Parks Scheme: Outlay ₹3,000 crore; max ₹1,000 crore/park (70% of CIF cost; 90% for NE & Hilly States); tenure FY 2020-21 to FY 2026-27 [S3].
• Approved parks: Gujarat, Himachal Pradesh, Andhra Pradesh — ₹1,000 cr grant each; selected from 13 state proposals [S3].
• PLI investment realised: ₹4,253.92 crore vs commitment ₹3,938.57 cr (Dec 2024) [S2].
• Cumulative sales under PLI: ₹2,315.44 crore till Sept 2025, including exports of ₹508.12 crore; imports avoided ₹1,807.32 crore [S2].
• Common Infrastructure Facilities (CIF) funded: CETP, solvent storage, warehouse, power substation, steam, cooling, logistics, CoE, testing lab [S3].

5. Multi-Dimensional Analysis

Economic - Pharma exports >$27 bn but value-add eroded by API import bill; PLI imports avoided ~₹1,807 cr signals modest, not transformative, substitution [S2]. - Bulk drug manufacturing largely private sector; government role limited to incentive/infra [S1].

Geopolitical / Strategic - Concentrated dependence on China for fermentation-based APIs (antibiotics, vitamins, statins) — exposed during COVID-19 and 2020 LAC standoff [S1]. - Diversification (to EU, Japan) constrained by Chinese cost advantage in fermentation & subsidised utilities.

Scientific / Technological - India lost competitiveness in fermentation technology (penicillin G, 7-ACA, vitamins) after 1990s liberalisation; PLI seeks revival in fermentation + chemical synthesis routes [S2].

Administrative - Federal interface — parks executed via State SPVs; delays in land/clearance noted in Bulk Drug Parks rollout [S3]. - 14 of 48 PLI projects yet to commission as of Dec 2024 — execution gap [S2].

Health Security - Disruption in API supply directly threatens availability of essential medicines (NLEM); WHO flags supply-chain resilience as core to UHC.

6. Recent Developments (last 12-18 months)

• 10 Mar 2026: PIB Annexure-I listing APIs with ≥70% Chinese share in FY24 & FY25 imports [S1].
• Sept 2025: Cumulative PLI sales cross ₹2,315 cr; exports ₹508 cr [S2].
• Dec 2024: 34/48 PLI projects commissioned; 25 bulk drugs domestically produced [S2].
• 2024: Inauguration of 27 greenfield bulk drug projects + 13 medical device plants under PLI [S2].

7. Prelims Hooks

• PLI Scheme for Bulk Drugs/KSMs/APIs outlay: ₹6,940 crore; targets 41 bulk drugs [S2].
• Bulk Drug Parks Scheme outlay: ₹3,000 crore; max ₹1,000 cr/park [S3].
• Three Bulk Drug Parks: Gujarat, Himachal Pradesh, Andhra Pradesh [S3].
• Both schemes approved on 20 March 2020 [S2][S3].
• Nodal: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers (NOT Ministry of Health) [S1].
• Centre's share for NE & Hilly States under Bulk Drug Parks: 90% of CIF [S3].
• Tenure of PLI (APIs/KSMs): FY 2020-21 to FY 2029-30 [S2].
• Tenure of Bulk Drug Parks Scheme: FY 2020-21 to FY 2026-27 [S3].
• PLI cumulative sales by Sept 2025: ₹2,315.44 crore; imports avoided: ₹1,807.32 crore [S2].
• Cabinet decision originated from recommendations of Katoch Committee on API self-reliance.
• Total selected PLI projects: 48; commissioned by Dec 2024: 34 producing 25 bulk drugs [S2].

8. Mains Relevance

• GS-III: Indian Economy — Industrial policy; Science & Tech — indigenisation of technology; Internal Security — supply-chain vulnerabilities.
• GS-II: Health (access to essential medicines); India-China bilateral.
• Probable stems: 1. "Examine the structural reasons for India's import dependence on China for APIs and evaluate the efficacy of PLI and Bulk Drug Parks schemes." 2. "Pharmaceutical supply chains are a national security concern. Discuss in the context of India-China economic relations." 3. "Critically assess India's progress towards Atmanirbharta in bulk drug manufacturing since 2020."

9. Related Topics to Study Next

• PLI Schemes (14 sectors) — flagship industrial policy umbrella.
• Pharma Vision 2020 / Pharmexcil — export ecosystem.
• National List of Essential Medicines (NLEM) & DPCO — price control link.
• Jan Aushadhi (PMBJP) — affordable generics depend on API supply.
• India-China trade deficit — pharma is a key contributor.
• Atmanirbhar Bharat Abhiyan — overall self-reliance push.
• WTO TRIPS & compulsory licensing — IP context.
• CDSCO & Drugs and Cosmetics Act, 1940 — regulatory backbone.

10. Common Errors / Trap Areas

• Confusing nodal ministry: it is Chemicals & Fertilizers (DoP), NOT Health & Family Welfare.
• Mixing up outlays: PLI bulk drugs ₹6,940 cr vs Bulk Drug Parks ₹3,000 cr (parks have a per-park cap of ₹1,000 cr).
• Number of parks = 3 (not 4 or 7); medical devices parks scheme is separate (4 parks).
• "API" ≠ formulation; India is surplus in formulations but deficit in APIs.
• PLI scheme covers 41 bulk drugs — not all APIs.

11. Sources

• [S1] APIs Imports from China — Department of Pharmaceuticals, PIB (10 Mar 2026) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2237414 — (tier 1)
• [S2] Strengthening domestic API manufacturing / PLI scheme details, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2197947 — (tier 1)
• [S3] Bulk Drug Park Scheme, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2224376 — (tier 1)